Hong Kong Drug Licence Applications and Acquisitions · RGYS|Global Licensing and Compliance Service Provider
Hong Kong pharmaceutical compliance · applications / acquisitions / ongoing maintenance Independent Third-Party Service Provider
HONG KONG DRUG LICENSING

As a licence holder, what responsibility do we have for building the company's “Compliance Culture”?

A complete explanation of the regulatory basis, Drew Tang’s recommendations and risk alerts. The original material dates from 2025; read it alongside the latest official requirements.

Original guide, 2025 edition: These FAQs are provided for topic-based reference and have not all been individually checked against current rules. Please confirm fees, personnel, renewal, changes and product requirements against the professional in-depth guide for the relevant licence type and the official requirements in force at the time.

Drug Office, Department of Health Chinese Medicines Board

Q400 · Category H: Licensed operations and routine regulatory oversight (Q351–Q400)
As a licence holder, the company's senior management has ultimate and non-delegable responsibility for establishing and maintaining a positive, organisation-wide “compliance culture”. This involves far more than appointing a compliance officer or writing a few SOPs. Your responsibilities include: 1. **Lead by example**: Demonstrate through all your words and actions the highest commitment to quality and compliance, and never compromise for short-term gain. 2. **Provide resources**: Ensure that the quality and compliance departments have sufficient and independent funding, staff and authority to fulfil their duties. 3. **Set expectations**: Use the company's quality policy and ongoing internal communications to make clear to every employee that compliance is everyone's responsibility, not just the quality department's. 4. **Encourage reporting and continuous improvement**: Create a “blame-free” environment that encourages staff to report errors, deviations and potential issues, treating them as opportunities to improve the system rather than reasons for punishment. 5. **Review performance**: Systematically review the performance of the quality system at regular management review meetings and set directions and targets for continuous improvement.

📘 Regulatory basis

Chapter 1, “Pharmaceutical Quality System”, of the PIC/S GMP Guide expressly emphasises that “management commitment” is a prerequisite for the success of the entire system. Regulators are increasingly focusing on this intangible “cultural” factor.

📗 Drew Tang's recommendations

We recommend that you treat building a compliance culture as a long-term, core strategic investment. Regularly discuss quality at company meetings, publicly recognise employees who contribute to compliance, and personally participate in key quality decisions. The message conveyed by these actions is far more powerful than any written document. A strong compliance culture is the company’s most robust competitive advantage.

📕 Risk notice

If the company culture condones or even encourages “shortcuts”, it is only a matter of time before a breach occurs, no matter how perfectly your SOPs are written. During an in-depth inspection, inspectors can quickly gauge the company's real culture through interviews with staff at all levels. If they believe that senior management pays lip service to compliance, they will lose confidence in all the company's records and commitments, which could lead to the most severe regulatory findings.

Back to Category H: Licensed Operations and Routine Oversight (Q351-Q400) Search more questions

YOUR NEXT STEP

Plan Your Hong Kong Pharmaceutical Licensing Project with Drew Tang

Business Manager Tang Shangyong (Drew Tang) will review your products, operating model, licence type and preparation requirements with you one-to-one. The precise service scope is confirmed in writing; pharmaceutical duties are carried out by legally qualified personnel, and approvals are determined by the competent authorities.

Book a Project Assessment ↗